

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	82618	SPASCUPREEL	
ARTG entry for	Medicine Liste	d	
Sponsor	Brauer Professional Pty Ltd		
Postal Address	PO Box 174, GLEN OSMOND, SA, 5064 Australia		
ARTG Start Date	1/05/2002		
Product Category	Medicine		
Status	Active		
Approval Area	Listed Medicine	es	
Constitution of			

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . SPASCUPREEL						
Product Type	Single Medicine Product	Effective Date	9/07/2019			
Permitted Indications						
Traditionally used in Homoeopathic medicine to decrease/reduce/relieve muscle cramps						
Traditionally used in Homoeopathic medicine to helps decrease/reduce/relieve mild muscle spasms/twitches						
Traditionally used in Homoeopathic medicine to decrease/reduce/relieve menstrual spasms/cramps						
Indication Requirements						
Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.						
Label statement: If symptoms persist, talk to your health professional.						

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect]. Homoeopathic product/preparation or medicine (or words to that effect)

If symptoms persist consult your healthcare practitioner (or words to that effect).

Contains lactose (or words to that effect).

Additional Product information

Page 1 of 2

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information



Australian Government

Department of Health

Therapeutic Goods Administration

Pack Size/Poison information						
Pack Size		Poison Schedule				
Components						
1. Formulation 1						
Dosage Form	Tablet, uncoated					
Route of Administration	Oral					
Visual Identification						
Active Ingredients						
Citrullus colocynthis fruit	flesh (Homeopathic)		15 mg			
cupric sulfate pentahydrat	te (Homeopathic)		15 mg			
dibasic magnesium phosp	ohate trihydrate (Homeopathic)		15 mg			
Gelsemium sempervirens	root and rhizome (Homeopathic)		15 mg			
Matricaria chamomilla who	ole plant (Homeopathic)		15 mg			
Other Ingredients (Excipients)						
lactose monohydrate						
magnesium stearate						

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information

This is not an ARTG Certificate document.